Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

19.2% of patients on Islatravir-Lenacapavir experienced mild adverse events, like dry mouth and nausea. The data was presented at the ID Week 2024. At 48 weeks, the investigational combination ...

US pharma company Gilead Sciences is seeking regulatory approval for the drug lenacapavir in a number of African countries – a key step towards making it available across the region, where ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...

What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...

U.S. pharma company Gilead Sciences is seeking regulatory approval for the drug lenacapavir in a number of African countries—a key step towards making it available across the region, where ...

吉利德创新药物Seladelpar也在本届进博会上迎来中国“首秀”。该药物已于2024年8月获得美国食品药品监督管理局（FDA）加速审批，为原发性胆汁性胆管炎患者的二线治疗带来了全新选择。作为一种慢性自身免疫性肝内胆汁淤积性疾病，原发性胆汁性胆管炎（ ...

In this open-label, active-controlled study, virologically suppressed adults on Biktarvy were randomly allocated in a 1:1 ratio to receive either oral islatravir 2 mg and lenacapavir 300 mg once a ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.